Elena Badykova

Dr. Elena Badykova

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Kristen Laura KoppKristen Laura Kopp
Kristen Laura Kopp
LMLukas J. Motloch
Lukas J. Motloch
Michael LichtenauerMichael Lichtenauer
Michael Lichtenauer
EBElke Boxhammer
Elke Boxhammer
UHUta C. Hoppe
Uta C. Hoppe
NZNaufal Zagidullin
Naufal Zagidullin
Background: Increased mortality and occurrence of cardiovascular (CV) outcomes during hospitalization and in short-term follow-up for moderate to severe SARS-CoV-2 infection have been associated with male sex, yet data regarding long-term outcomes by sex and COVID-19 variant (Alpha, Delta, and Omicron) are limited. Methods: This prospective study of 4882 patients examines potential differences by sex in the occurrence of primary combined cardiovascular outcomes (CV death, CV hospitalization, myocardial infarction (MI), stroke, pulmonary embolism) as well as secondary outcomes (CV death, cardiovascular hospitalizations, myocardial infarction, stroke, pulmonary embolism) at 18-month follow-up after urgent hospitalization for SARS-CoV-2-associated pneumonia, as well as evaluating for differences during the three COVID-19 waves. Survival rate was analyzed for the entire cohort by sex and SARS-CoV-2 variant and adjusted for age using the multiple Kaplan–Meier method. To compare survival in groups of men and women for each wave, the Gehan–Wilcoxon test was applied with significance p < 0.05. Univariate Cox proportional hazards models were used to search for potential risk factors of CV death at 18-months follow-up separately for men and women in each COVID-19 wave. Results: Men had significantly higher 18-month CV mortality compared to women in the Delta wave (6.13% men vs. 3.62% women, p = 0.017). Although men had higher percentages of all other CV endpoints (excepting pulmonary embolism) at follow-up during the Delta wave, none were significant compared with women, except for the combined CV endpoint (16.87% men vs. 12.61% women, p = 0.017). No significant differences by sex in CV outcomes were seen during the Alpha and Omicron variants. Discrepancies in CV outcomes in demographical data and concomitant disease between the COVID-19 variants of concern existed. Conclusions: Higher male mortality and higher but non-significant incidences of CV outcomes occurred during the Delta wave of the COVID-19 pandemic, with the lowest incidence of CV outcomes observed during the Omicron variant.

20 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Kristen Laura KoppKristen Laura Kopp
Kristen Laura Kopp
Michael LichtenauerMichael Lichtenauer
Michael Lichtenauer
VPVera Paar
Vera Paar
UHUta C. Hoppe
Uta C. Hoppe
RRRozana Rakhimova
Rozana Rakhimova
NZNaufal Zagidullin
Naufal Zagidullin
Background: ST-segment-elevation myocardial infarction (STEMI) continues to be associated with substantial short- and long-term cardiovascular (CV) mortality despite advances in treatment. Accurate early risk stratification remains critical for optimizing outcomes. Emerging biomarkers including CRP, sST2, and FABP may enhance predictive precision beyond classical markers. This study aimed to evaluate the prognostic value of these biomarkers for in-hospital and 18-month post-discharge CV mortality in STEMI patients. Methods: In this prospective, single-center study, 179 consecutive STEMI patients admitted September 2020–June 2021 underwent biomarker evaluation upon admission. Serum concentrations of CRP, sST2, and H-FABP were measured by ELISA. Patients were followed for in-hospital outcomes and post-discharge mortality during 18-month follow-up (FU) (last patient, last visit January 2023). ROC analysis was used to determine biomarker cut-off values. Cox regression and Kaplan-Meier analyses assessed associations with mortality. Results: In-hospital mortality was 7.8% (14/179). Elevated CRP (>11 mg/L) was significantly associated with higher in-hospital mortality (21.4% vs. 3.7%, p < 0.01). sST2 and H-FABP showed trends toward worse outcomes at higher levels, although their independent predictive value was less robust. Cox regression identified CRP > 11 mg/L (HR = 4.93, p < 0.01), admission glucose, and reduced GFR as independent predictors of in-hospital mortality. During FU, 18 of 165 discharged patients (10.1%) experienced CV death. Higher sST2 levels were significantly associated with post-discharge mortality in midterm FU (p = 0.041). Conclusions: We could show that CRP > 11 mg/L is a strong predictor of in-hospital mortality while elevated sST2 is associated with CV mortality during midterm FU in STEMI patients. Incorporating these biomarkers into clinical risk models may enhance early risk prediction and identify patients at higher risk for post-discharge events.

30 June 2021 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
Yanina TimashevaYanina Timasheva
Yanina Timasheva
MBMarat Badykov
Marat Badykov
LALeysan Зинуровна Akhmadishina
Leysan Зинуровна Akhmadishina
TNTimur Nasibullin
Timur Nasibullin
EBElena Badykova
Elena Badykova
NZNaufal Zagidullin
Naufal Zagidullin

7 March 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
EBElena Badykova
Elena Badykova
MBM. R. Badykov
M. R. Badykov
VPV. V. Plechev
V. V. Plechev
ISI. Sh. Sagitov
I. Sh. Sagitov
ILIrina Lakman
Irina Lakman
NZNaufal Zagidullin
Naufal Zagidullin
Анализ отдалённых сердечно-сосудистых событий у пациентов с дисфункцией синусового узла и имплантированым электрокардиостимулятором

13 April 2025 in Siberian Journal of Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
AAA. M. Amineva
A. M. Amineva
ILIrina Lakman
Irina Lakman
EBElena Badykova
Elena Badykova
MSM. N. Shamuratov
M. N. Shamuratov
RRR. F. Rakhimova
R. F. Rakhimova
NZNaufal Zagidullin
Naufal Zagidullin
Psoriasis is a chronic immune-inflammatory dermatological disease that affects not only the skin, but can also cause systemic inflammation, increasing cardiovascular endpoints.Aim: To examine long-term cardiovascular endpoints in patients with coronary heart disease (CHD), psoriasis and their combination in a prospective observational study.Material and Methods. 3 groups of patients with moderate-to-severe psoriasis (n = 30), coronary artery disease (CHD) (n = 32) and psoriasis + coronary artery disease (n = 28) were enrolled in the study. They were observed for 48 months in terms of unfavourable endpoints (exacerbation of psoriasis, cardiac vascular hospitalizations, death, heart attacks and strokes).Results. The CHD group had a higher frequency of diabetes mellitus (DM) (30 vs. 3.6%, p = 0.008) and worse systolic blood pressure (SBP) control (142 (134.0–149.8) vs. 136 (128.0–144.6) mmHg, p = 0.048) compared with the CHD comorbidity group. Cardiovascular mortality was higher in patients with CHD compared with the group with psoriasis (p = 0.027) and CHD with psoriasis (p = 0.040). The rate of cardiovascular hospitalizations did not differ in pairs with CHD versus CHD and exacerbations of psoriasis in the groups with psoriasis and psoriasis with CHD (p > 0.05), but the total rate of both types of hospitalizations was higher in the group of patients with CHD and psoriasis (p = 0.009).Conclusion. In case of comorbidity of psoriasis with CHD, the frequency of cardiovascular hospitalizations and exacerbation of psoriasis increased. CHD reduced the time to the first exacerbation of psoriasis.

14 April 2024 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
AAA. M. Amineva
A. M. Amineva
ILIrina Lakman
Irina Lakman
EBElena Badykova
Elena Badykova
RRR. F. Rakhimova
R. F. Rakhimova
SDS. S. Dozhdev
S. S. Dozhdev
NZNaufal Zagidullin
Naufal Zagidullin
Aim. To study serum biomarker profile in patients with coronary artery disease (CAD) and psoriasis and the impact on the incidence of hospitalization for cardiovascular reasons and psoriasis.Material and methods. The study included 90 patients divided into following 3 groups: with psoriasis (n=30), coronary artery disease (CAD) (n=30) and CAD+psoriasis (n=30) in whom serum biomarkers were determined at the beginning of the study (growth stimulation expressed gene 2, N-terminal pro-brain natriuretic peptide (NT-proBNP), interleukin-17 and tumor necrosis factor alpha) and hospitalization rates were monitored over 4 years.Results. There was a significant difference in the concentrations of all biomarkers between the groups (p<0,05), with the maximum values being in the CAD+psoriasis group, except for NT-proBNP. In regression analysis, risk factors for cardiovascular hospitalizations were psoriasis (p=0,049) and increased NT-proBNP concentrations (p<0,001).Conclusion. Comorbidity leads to an increase in the serum concentration of biomarkers, while the risk factors for cardiovascular hospitalization were psoriasis and serum NT-proBNP level.